Abstract: The HOTAIR/miR-214/ST6GAL1 axis commands the CRC malignancy by modifying c-Met with sialylation and activating JAK2/STAT3 pathway. Our study presents novel insights into CRC progression and provided prospective therapeutic target for CRC.
Introduction
Colorectal cancer (CRC) remains a leading cause of cancer-related mortality worldwide, often due to late-stage diagnosis and the development of drug resistance. While scientists have long recognized that oncogenic proteins drive tumor progression, the specific role of post-translational modifications—particularly glycosylation—is still being mapped out. Glycosylation involves the attachment of sugar molecules, such as sialic acid, to proteins, which can drastically alter their function and signaling activity.
This study investigates a complex regulatory network that bridges non-coding RNA activity with these sugar-based protein modifications. The researchers identified a specific molecular axis—HOTAIR/miR-214/ST6GAL1—that controls the activation of the c-Met oncogene through a process called sialylation, providing a new perspective on how CRC spreads and survives.
Methods
The research team employed a multi-disciplinary approach combining molecular biology, glycan analysis, and animal models to validate their findings:
- Expression Profiling: Used qRT-PCR and Western blotting to measure levels of HOTAIR, miR-214, and ST6GAL1 in 42 pairs of human CRC tissues and various cell lines, including chemotherapy-resistant variants.
- Interaction Studies: Utilized Dual-luciferase reporter assays and RNA Immunoprecipitation (RIP) to prove that HOTAIR physically binds to miR-214, which in turn targets the messenger RNA of ST6GAL1.
- Glycan Analysis: Performed Lectin pull-down assays using Sambucus nigra lectin (SNA), which specifically binds to alpha2,6-linked sialic acid, to track the modification of the c-Met protein.
- Functional & In Vivo Assays: Measured cell proliferation, invasion, and colony formation. Xenograft and metastasis models in nude mice were used to observe tumor spread in a living system.
Results
The "Sponge" Mechanism and Pathway Activation
The study confirms that the long non-coding RNA (lncRNA) HOTAIR functions as a competitive endogenous RNA (ceRNA), or a molecular "sponge." It effectively sequesters miR-214, preventing this microRNA from performing its natural role of suppressing the enzyme ST6GAL1.
When ST6GAL1 levels rise, the enzyme specifically targets the c-Met receptor, adding sialic acid molecules to it. This sialylation acts as a "spark" that ignites the JAK2/STAT3 cascade, a major signaling pathway that instructs cancer cells to multiply rapidly and migrate to distant organs like the lungs and liver.
Clinical Significance and Prognosis
Analysis of clinical samples from 42 CRC patients revealed that high levels of HOTAIR and ST6GAL1, combined with low levels of miR-214, were strongly associated with advanced tumor stages (III and IV). Specifically, HOTAIR expression was significantly higher in patients who had already developed metastasis.
Furthermore, survival analysis demonstrated that patients with high HOTAIR expression had a significantly lower overall survival rate compared to those with low expression, marking it as a potent prognostic biomarker.
Therapeutic Synergy
The researchers found that the pro-cancer effects of HOTAIR could be reversed by re-introducing miR-214 or by inhibiting c-Met directly. Most notably, combining HOTAIR knockdown with a c-Met inhibitor (AMG-208) was more effective at inhibiting tumor growth in mouse models than either treatment alone, suggesting a potential strategy for combination therapy in the clinic.
Discussion and Conclusion
This research highlights the critical role of the HOTAIR/miR-214/ST6GAL1 axis in driving CRC malignancy. By linking lncRNA regulation to protein sialylation, the study identifies a novel mechanism of oncogenic signaling. While the clinical cohort was relatively small, the findings provide a strong rationale for targeting this axis to overcome metastasis. Future work will need to address the challenges of delivering RNA-based therapies and explore whether this axis also contributes to chemotherapy resistance, potentially offering a way to sensitize resistant tumors to standard treatments.
Summary updated